iSAM Funds UK Ltd Buys 38,914 Shares of Pfizer Inc. $PFE

Key Points

• iSAM Funds UK Ltd more than doubled its Pfizer position in the second quarter, buying 38,914 additional shares for a total of 69,300 shares valued at approximately $1.67 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer beat quarterly earnings and revenue expectations, reporting $0.77 in EPS and $15.03 billion in revenue, while issuing full-year 2026 EPS guidance of $2.80–$3.00.
• The stock offers a 5.9% dividend yield, but its payout ratio is elevated at 226.32%; analysts remain cautious, with a consensus “Hold” rating and an average price target of $28.28 versus the reported $29.02 share price.

iSAM Funds UK Ltd lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 128.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,300 shares of the biopharmaceutical company's stock after acquiring an additional 38,914 shares during the period. Pfizer makes up approximately 1.2% of iSAM Funds UK Ltd's holdings, making the stock its 13th biggest holding. iSAM Funds UK Ltd's holdings in Pfizer were worth $1,669,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank raised its position in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Sei Investments Co. raised its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC lifted its holdings in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock valued at $2,480,000 after purchasing an additional 31,896 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.7%

NYSE:PFE opened at $29.02 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $165.42 billion, a PE ratio of 38.19, a PEG ratio of 1.92 and a beta of 0.34. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.09. The stock has a 50-day simple moving average of $25.79 and a 200 day simple moving average of $26.32.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. JPMorgan Chase & Co. decreased their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and reduced their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. UBS Group reissued a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Wolfe Research restated an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source